Ying Chen1, Shaoyi Miao2, Wancheng Zhao3. 1. Department of Ultrasound, Xiaoshan Traditional Chinese Medical Hospital Hangzhou 311200, China. 2. Department of Respiratory, The Fifth Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China. 3. Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University Shenyang 110000, China.
Abstract
OBJECTIVE: Immune checkpoint inhibitors (ICI) has achieved remarkable clinical benefit in advanced lung adenocarcinoma (LUAD). However, effective clinical use of ICI agents is encumbered by the high rate of innate resistance. The aim of our research is to identify significant gene mutations which can predict clinical benefit of immune checkpoint inhibitors in LUAD. METHODS: The "mafComapre" function of "MafTools" package was used to screen the differentially mutated genes between durable clinical benefit (DCB) group and no durable clinical benefit (NDB) group based on the somatic mutation data from NSCLc_PD1_mSK_2018. Machine learning was performed to select significantly mutated genes to accurately classify patients into DCB group and NDB group. A nomogram model was constructed based on the significantly mutated genes to predict the susceptibility of patients to ICI. Finally, we explored the correlation between two classifications of immune cell infiltration, PD-1 and PD-L1 expression, tumor mutational burden (TMB) and prognosis. RESULTS: Through utilize machine learning, 6 significantly mutated genes were obtained from 8 differentially mutated genes and used to accurately classify patients into DCB group and NDB group. The DCA curve and clinical impact curve revealed that the patients can benefit from the decisions made based on the nomogram model. Patients highly sensitive to ICI have elevated immune activity, higher expression of PD-1 and PD-L1, increased TMB, and well prognosis if they accept ICI treatment. CONCLUSIONS: Our research selected 6 significantly mutated genes that can predict clinical benefit of ICI in LUAD patients. AJTR
OBJECTIVE: Immune checkpoint inhibitors (ICI) has achieved remarkable clinical benefit in advanced lung adenocarcinoma (LUAD). However, effective clinical use of ICI agents is encumbered by the high rate of innate resistance. The aim of our research is to identify significant gene mutations which can predict clinical benefit of immune checkpoint inhibitors in LUAD. METHODS: The "mafComapre" function of "MafTools" package was used to screen the differentially mutated genes between durable clinical benefit (DCB) group and no durable clinical benefit (NDB) group based on the somatic mutation data from NSCLc_PD1_mSK_2018. Machine learning was performed to select significantly mutated genes to accurately classify patients into DCB group and NDB group. A nomogram model was constructed based on the significantly mutated genes to predict the susceptibility of patients to ICI. Finally, we explored the correlation between two classifications of immune cell infiltration, PD-1 and PD-L1 expression, tumor mutational burden (TMB) and prognosis. RESULTS: Through utilize machine learning, 6 significantly mutated genes were obtained from 8 differentially mutated genes and used to accurately classify patients into DCB group and NDB group. The DCA curve and clinical impact curve revealed that the patients can benefit from the decisions made based on the nomogram model. Patients highly sensitive to ICI have elevated immune activity, higher expression of PD-1 and PD-L1, increased TMB, and well prognosis if they accept ICI treatment. CONCLUSIONS: Our research selected 6 significantly mutated genes that can predict clinical benefit of ICI in LUAD patients. AJTR
Authors: Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig Journal: Science Date: 2018-01-04 Impact factor: 47.728
Authors: Julie R Brahmer; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Jin Zhang; Gregory M Lubiniecki; Anne C Deitz; Reshma Rangwala; Martin Reck Journal: Lancet Oncol Date: 2017-11-09 Impact factor: 41.316
Authors: Jérôme Biton; Audrey Mansuet-Lupo; Nicolas Pécuchet; Marco Alifano; Hanane Ouakrim; Jennifer Arrondeau; Pascaline Boudou-Rouquette; François Goldwasser; Karen Leroy; Jeremy Goc; Marie Wislez; Claire Germain; Pierre Laurent-Puig; Marie-Caroline Dieu-Nosjean; Isabelle Cremer; Ronald Herbst; Hélène Blons; Diane Damotte Journal: Clin Cancer Res Date: 2018-05-15 Impact factor: 12.531
Authors: Joshua D Campbell; Anton Alexandrov; Jaegil Kim; Jeremiah Wala; Alice H Berger; Chandra Sekhar Pedamallu; Sachet A Shukla; Guangwu Guo; Angela N Brooks; Bradley A Murray; Marcin Imielinski; Xin Hu; Shiyun Ling; Rehan Akbani; Mara Rosenberg; Carrie Cibulskis; Aruna Ramachandran; Eric A Collisson; David J Kwiatkowski; Michael S Lawrence; John N Weinstein; Roel G W Verhaak; Catherine J Wu; Peter S Hammerman; Andrew D Cherniack; Gad Getz; Maxim N Artyomov; Robert Schreiber; Ramaswamy Govindan; Matthew Meyerson Journal: Nat Genet Date: 2016-05-09 Impact factor: 38.330
Authors: Antje Tunger; Ulrich Sommer; Rebekka Wehner; Anne Sophie Kubasch; Marc-Oliver Grimm; Michael Philipp Bachmann; Uwe Platzbecker; Martin Bornhäuser; Gustavo Baretton; Marc Schmitz Journal: J Clin Med Date: 2019-09-25 Impact factor: 4.241